ClinicalTrials.gg
CompletedNCT02959944iNTEGRATEUpdated Mar 30, 2023Results posted

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

A Phase 3 interventional study of ibrutinib and Placebo in Chronic Graft Versus Host Disease, sponsored by Pharmacyclics LLC.. Completed at 102 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-30.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome — none open to participants now, 1 under way, 1 of them phase 3. ibrutinib · Bronchiolitis Obliterans Syndrome.

Enrollment
3rd of 11
193 · median 19
Started
2017
the only one that year
Phase 3
3 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
4 of 11
Pharmacyclics LLC.

Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 3 in phase 3, and was the 5th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

None of the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome is open now. The open studies under Bronchiolitis Obliterans Syndrome, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome as a file.
02

Study summary

To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

03

Conditions studied

  • Chronic Graft Versus Host Disease

Keywords

  • chronic graft versus host disease
  • PCYC1140
  • PCYC1140IM
  • 1140
  • Ibrutinib
  • GVHD
  • Steroid dependent
  • refractory
  • chronic
  • PCI32765
  • IMBRUVICA
  • Pharmacyclics
  • PCYC
  • graft versus host disease
  • immunology
  • new onset graft versus host disease
  • INTEGRATE
  • Corticosteroids
  • prednisone
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • New onset moderate or severe cGVHD as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project Criteria
  • Need for systemic treatment with for cGVHD
  • No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP])
  • Participants may be receiving other for the prophylaxis or treatment of acute but if the subject is receiving prednisone for prophylaxis or treatment of acute GVHD it must be at or below 0.5 mg/kg/d
  • Age ≥12 years old
  • or Lansky (subjects \<16 years) performance status ≥60

Key Exclusion Criteria:

  • Received any previous systemic treatment for cGVHD with the exception of corticosteroids administered for cGVHD within the 72 hours prior to signing the form.
  • Inability to begin a prednisone dose ≥0.5 mg/kg/d for the treatment of cGVHD
  • Any uncontrolled infection or active infection requiring ongoing systemic treatment
  • Progressive underlying malignant disease or any post-transplant lymphoproliferative disease
  • Known bleeding disorders
  • Active virus (HCV) or virus (HBV)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Ibrutinib + Prednisone

    Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 \[CYP\] inhibitors or hepatic dysfunction as applicable. Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses.

    Drug: ibrutinib · Drug: Prednisone

  • Placebo comparator
    Placebo + Prednisone

    Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses.

    Drug: Placebo · Drug: Prednisone

Interventions

  • Ibrutinib capsules administered orally daily

    Also known as: IMBRUVICA®, PCI-32765

  • DrugPlacebo

    Placebo capsules administered orally daily

  • Prednisone administered daily

06

What researchers measure

Primary outcomes

  1. Primary Analysis: Response Rate at 48 Weeks

    Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: 48 weeks (Cumulatively up to 30 March 2020)

  2. Final Analysis: Response Rate at 48 Weeks

    Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: 48 weeks (Cumulatively up to 12 July 2021)

Secondary outcomes

  1. Primary Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD

    The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.

    Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 30 March 2020)

  2. Final Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD

    The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.

    Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)

  3. Primary Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants

    The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.

    Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (cumulatively up to 30 March 2020)

  4. Final Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants

    The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.

    Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)

  5. Primary Analysis: Response Rate at 24 Weeks

    Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: 24 weeks (Cumulatively up to 30 March 2020)

  6. Final Analysis: Response Rate at 24 Weeks

    Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: 24 weeks (Cumulatively up to 12 July 2021)

  7. Primary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits

    Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.

    Time frame: Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)

  8. Final Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits

    Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.

    Time frame: Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)

  9. Primary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days

    Time frame: 24 weeks (Cumulatively up to 30 March 2020)

  10. Final Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days

    Time frame: 24 weeks (Cumulatively up to 12 July 2021)

  11. Primary Analysis: Overall Survival (OS)

    OS was defined as the time of randomization until the time of death due to any cause, in months.

    Time frame: Median time on study (cumulatively up to 30 March 2020) was 19.8 months and 18.4 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.

  12. Final Analysis: OS

    OS was defined as the time of randomization until the time of death due to any cause, in months.

    Time frame: Median time on study (cumulatively up to 12 July 2021) was 33.1 months and 32.5 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.

  13. Primary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time

    Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.

    Time frame: Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)

  14. Final Analysis: DOR for Participants Who Had PR or CR at Any Time

    Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.

    Time frame: Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)

  15. Primary Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone

    AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.

    Time frame: From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 30 March 2020), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.

  16. Final Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone

    AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.

    Time frame: From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 12 July 2021), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.

07

Results

Posted May 4, 2021

Participant flow

Participants were enrolled at 66 sites overall: 24 sites in North America, and 42 sites in the rest of the world.

Participant flow — Overall Study
MilestoneIbrutinib + PrednisonePlacebo + Prednisone
Started9598
Received at least 1 dose of study drug9496
Completed9598
Not completed00

Outcome measures

PrimaryPrimary Analysis: Response Rate at 48 Weeks

Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
48 weeks (Cumulatively up to 30 March 2020)
Reported as:
Number · percentage of participants
Primary Analysis: Response Rate at 48 Weeks
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Response Rate at 48 Weeks41.136.7
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.5384 (P-value is computed using non-stratified Chi-Square test.) · Difference in rates: 0.043 · 95% CI -0.094 to 0.181Confidence interval is computed using normal approximation.
PrimaryFinal Analysis: Response Rate at 48 Weeks

Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
48 weeks (Cumulatively up to 12 July 2021)
Reported as:
Number · percentage of participants
Final Analysis: Response Rate at 48 Weeks
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: Response Rate at 48 Weeks41.136.7
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.5384 (P-value is computed using non-stratified Chi-Square test.) · Difference in rates: 0.043 · 95% CI -0.094 to 0.181Confidence interval is computed using normal approximation.
SecondaryPrimary Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD

The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.

Time frame:
Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 30 March 2020)
Reported as:
Number · proportion of participants
Primary Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD
proportion of participantsIbrutinib + PrednisonePlacebo + Prednisone
3 Months0.042 (0.014 to 0.097)0.021 (0.004 to 0.066)
6 Months0.229 (0.149 to 0.320)0.216 (0.140 to 0.304)
9 Months0.318 (0.225 to 0.415)0.322 (0.231 to 0.417)
12 Months0.392 (0.290 to 0.492)0.356 (0.260 to 0.453)
15 Months0.419 (0.314 to 0.520)0.356 (0.260 to 0.453)
18 Months0.419 (0.314 to 0.520)0.356 (0.260 to 0.453)
21 Months—0.425 (0.299 to 0.545)
24 Months—0.425 (0.299 to 0.545)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.324 (Gray's chi-square test (p-value) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy.)
SecondaryFinal Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD

The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.

Time frame:
Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)
Reported as:
Number · proportion of participants
Final Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD
proportion of participantsIbrutinib + PrednisonePlacebo + Prednisone
3 Months0.042 (0.014 to 0.097)0.021 (0.004 to 0.066)
6 Months0.218 (0.140 to 0.308)0.219 (0.142 to 0.307)
9 Months0.318 (0.225 to 0.414)0.326 (0.234 to 0.422)
12 Months0.406 (0.305 to 0.505)0.359 (0.263 to 0.455)
15 Months0.439 (0.336 to 0.538)0.359 (0.263 to 0.455)
18 Months0.450 (0.346 to 0.549)0.369 (0.272 to 0.466)
21 Months0.495 (0.388 to 0.593)0.391 (0.292 to 0.489)
24 Months0.495 (0.388 to 0.593)0.391 (0.292 to 0.489)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.281 (Gray's chi-square test (p-value) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy.)
SecondaryPrimary Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants

The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.

Time frame:
Months 3, 6, 9, 12, 15, 18, 21, 24 (cumulatively up to 30 March 2020)
Reported as:
Number · proportion of participants
Primary Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants
proportion of participantsIbrutinib + PrednisonePlacebo + Prednisone
3 Months0.011 (0.001 to 0.052)0.000 (NA to NA)
6 Months0.142 (0.079 to 0.222)0.134 (0.075 to 0.210)
9 Months0.220 (0.141 to 0.310)0.207 (0.132 to 0.294)
12 Months0.256 (0.170 to 0.350)0.241 (0.160 to 0.331)
15 Months0.285 (0.193 to 0.383)0.241 (0.160 to 0.331)
18 Months0.313 (0.210 to 0.422)0.241 (0.160 to 0.331)
21 Months0.376 (0.252 to 0.499)0.268 (0.174 to 0.370)
24 Months0.421 (0.280 to 0.556)0.268 (0.174 to 0.370)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.275 (Gray's chi-square test (p-value) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy.)
SecondaryFinal Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants

The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.

Time frame:
Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)
Reported as:
Number · proportion of participants
Final Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants
proportion of participantsIbrutinib + PrednisonePlacebo + Prednisone
3 Months0.011 (0.001 to 0.052)0.000 (NA to NA)
6 Months0.143 (0.080 to 0.224)0.136 (0.076 to 0.213)
9 Months0.222 (0.142 to 0.313)0.221 (0.143 to 0.309)
12 Months0.280 (0.191 to 0.375)0.264 (0.179 to 0.356)
15 Months0.314 (0.220 to 0.412)0.274 (0.188 to 0.367)
18 Months0.349 (0.251 to 0.448)0.285 (0.197 to 0.379)
21 Months0.372 (0.272 to 0.472)0.307 (0.216 to 0.402)
24 Months0.406 (0.303 to 0.507)0.307 (0.216 to 0.402)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.216 (Gray's chi-square test (p-value) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy.)
SecondaryPrimary Analysis: Response Rate at 24 Weeks

Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
24 weeks (Cumulatively up to 30 March 2020)
Reported as:
Number · percentage of participants
Primary Analysis: Response Rate at 24 Weeks
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Response Rate at 24 Weeks47.454.1
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.3510 (P-value was computed using non-stratified Chi-Square test.) · Difference in rates: -0.067 · 95% CI -0.208 to 0.074Confidence interval is computed using normal approximation.
SecondaryFinal Analysis: Response Rate at 24 Weeks

Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
24 weeks (Cumulatively up to 12 July 2021)
Reported as:
Number · percentage of participants
Final Analysis: Response Rate at 24 Weeks
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: Response Rate at 24 Weeks47.454.1
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.3510 (P-value was computed using non-stratified Chi-Square test.) · Difference in rates: -0.067 · 95% CI -0.208 to 0.074Confidence interval is computed using normal approximation.
SecondaryPrimary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits

Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.

Time frame:
Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)
Reported as:
Number · percentage of participants
Primary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits38.926.5
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.0659 (P-value is computed using non-stratified Chi-Square test.) · Difference in rates: 0.124 · 95% CI -0.007 to 0.256Confidence interval is computed using normal approximation.
SecondaryFinal Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits

Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.

Time frame:
Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)
Reported as:
Number · percentage of participants
Final Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits43.230.6
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.0708 (P-value is computed using non-stratified Chi-Square test.) · Difference in rates: 0.125 · 95% CI -0.010 to 0.261
SecondaryPrimary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
Time frame:
24 weeks (Cumulatively up to 30 March 2020)
Reported as:
Number · percentage of participants
Primary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days40.045.9
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.4064 (P-value was computed using non-stratified Chi-Square test.) · Difference in rates: -0.059 · 95% CI -0.199 to 0.080Confidence interval was computed using normal approximation.
SecondaryFinal Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
Time frame:
24 weeks (Cumulatively up to 12 July 2021)
Reported as:
Number · percentage of participants
Final Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
percentage of participantsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days41.145.9
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Chi-squared · p = 0.4955 (P-value was computed using non-stratified Chi-Square test.) · Difference in rates: -0.049 · 95% CI -0.188 to 0.091Confidence interval was computed using normal approximation.
SecondaryPrimary Analysis: Overall Survival (OS)

OS was defined as the time of randomization until the time of death due to any cause, in months.

Time frame:
Median time on study (cumulatively up to 30 March 2020) was 19.8 months and 18.4 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.
Reported as:
Median · months
Primary Analysis: Overall Survival (OS)
monthsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Overall Survival (OS)NA (30.0 to NA)NA (NA to NA)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Hazard ratio (hr): 0.994 · 95% CI 0.507 to 1.949Hazard ratio is estimated using unstratified Cox regression model with treatment as the only covariate.
SecondaryFinal Analysis: OS

OS was defined as the time of randomization until the time of death due to any cause, in months.

Time frame:
Median time on study (cumulatively up to 12 July 2021) was 33.1 months and 32.5 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.
Reported as:
Median · months
Final Analysis: OS
monthsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: OSNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Hazard ratio (hr): 1.061 · 95% CI 0.591 to 1.904Hazard ratio is estimated using unstratified Cox regression model with treatment as the only covariate.
SecondaryPrimary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time

Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.

Time frame:
Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)
Reported as:
Median · months
Primary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time
monthsIbrutinib + PrednisonePlacebo + Prednisone
Primary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time19.8 (7.4 to NA)10.0 (6.5 to 13.1)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Regression, Cox · p = 0.1010 · Hazard ratio (hr): 0.697 · 95% CI 0.451 to 1.076
SecondaryFinal Analysis: DOR for Participants Who Had PR or CR at Any Time

Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.

Time frame:
Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)
Reported as:
Median · months
Final Analysis: DOR for Participants Who Had PR or CR at Any Time
monthsIbrutinib + PrednisonePlacebo + Prednisone
Final Analysis: DOR for Participants Who Had PR or CR at Any Time19.1 (7.4 to NA)10.2 (6.5 to 17.1)
Statistical analysis
  • Ibrutinib + Prednisone vs Placebo + Prednisone · Regression, Cox · p = 0.1004 · Hazard ratio (hr): 0.717 · 95% CI 0.482 to 1.068
SecondaryPrimary Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone

AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.

Time frame:
From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 30 March 2020), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.
Reported as:
Count of participants · Participants
Primary Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone
ParticipantsIbrutinib + PrednisonePlacebo + Prednisone
Any TEAE9395
Any Grade ≥ 3 TEAE6064
Any Ibrutinib-/Placebo-Related TEAE6658
Any Grade ≥ 3 Ibrutinib-/Placebo-Related TEAE3228
Any Corticosteroid-Related TEAE7177
Any Grade ≥ 3 Corticosteroid-Related TEAE3236
Any TEAE Leading to Discontinuation (DC) of Any Treatment2124
Any TEAE Leading to DC of Ibrutinib/Placebo2123
Any TEAE Leading to DC of Corticosteroid88
Any Treatment Emergent SAE (TESAE)4648
Any Grade ≥ 3 TESAE4346
Any Treatment-Related TESAE2728
Any Ibrutinib/Placebo Treatment-Related TESAE2419
Any Corticosteroid Treatment-Related TESAE2427
Any Fatal TEAE107
SecondaryFinal Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone

AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.

Time frame:
From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 12 July 2021), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.
Reported as:
Count of participants · Participants
Final Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone
ParticipantsIbrutinib + PrednisonePlacebo + Prednisone
Any TEAE9395
Any Grade ≥ 3 TEAE6464
Any Ibrutinib-/Placebo-Related TEAE6757
Any Grade ≥ 3 Ibrutinib-/Placebo-Related TEAE3527
Any Corticosteroid-Related TEAE7276
Any Grade ≥ 3 Corticosteroid-Related TEAE3435
Any TEAE Leading to Discontinuation (DC) of Any Treatment2328
Any TEAE Leading to DC of Ibrutinib/Placebo2227
Any TEAE Leading to DC of Corticosteroid109
Any Treatment Emergent SAE (TESAE)4947
Any Grade ≥ 3 TESAE4645
Any Treatment-Related TESAE2927
Any Ibrutinib/Placebo Treatment-Related TESAE2618
Any Corticosteroid Treatment-Related TESAE2626
Any Fatal TEAE126

Adverse events

Collected over From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 12 July 2021), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib23/94 (24.5%)51/94 (54.3%)88/94 (93.6%)
Placebo22/96 (22.9%)49/96 (51%)92/96 (95.8%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventIbrutinibPlacebo
PNEUMONIAInfections and infestations6/949/96
INFLUENZAInfections and infestations4/944/96
ACUTE MYELOID LEUKAEMIA RECURRENTNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/944/96
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/944/96
CHRONIC GRAFT VERSUS HOST DISEASEImmune system disorders3/943/96
CELLULITISInfections and infestations3/940/96
PYREXIAGeneral disorders1/943/96
GRAFT VERSUS HOST DISEASEImmune system disorders0/943/96
PERICARDIAL EFFUSIONCardiac disorders2/940/96
DIARRHOEAGastrointestinal disorders2/941/96
Most frequent other events
Showing 10 of 70
Most frequent other events
EventIbrutinibPlacebo
COUGHRespiratory, thoracic and mediastinal disorders21/9429/96
INSOMNIAPsychiatric disorders26/9418/96
OEDEMA PERIPHERALGeneral disorders25/9413/96
THROMBOCYTOPENIABlood and lymphatic system disorders18/9415/96
FATIGUEGeneral disorders17/9418/96
MUSCLE SPASMSMusculoskeletal and connective tissue disorders17/9416/96
PYREXIAGeneral disorders7/9416/96
ALANINE AMINOTRANSFERASE INCREASEDInvestigations7/9416/96
VOMITINGGastrointestinal disorders15/948/96
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations15/9415/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibrutinib + PrednisonePlacebo + PrednisoneTotal
Mean50.0 ± 14.4851.1 ± 14.9950.6 ± 14.71
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib + PrednisonePlacebo + PrednisoneTotal
Female343367
Male6165126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib + PrednisonePlacebo + PrednisoneTotal
Hispanic or Latino527
Not Hispanic or Latino7878156
Unknown or Not Reported121830
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib + PrednisonePlacebo + PrednisoneTotal
American Indian or Alaska Native101
Asian271946
Native Hawaiian or Other Pacific Islander101
Black or African American6410
White4758105
More than one race112
Unknown or Not Reported121628
08

Study locations

102 sites
  • Arizona Oncology - Scottsdale - Cancer Transplant Institute Location /ID# 1140-1120
    Scottsdale, Arizona 85258-4547, United States
  • LPCH Stanford /ID# 1140-1128
    Palo Alto, California 94304, United States
  • Ucsf /Id# 1140-0003
    San Francisco, California 94143, United States
  • Stanford University/Stanford Cancer Center, Pasteur Drive /ID# 1140-0400
    Stanford, California 94305, United States
  • UCHSC Anschultz Cancer Pavilion /ID# 1140-0068
    Aurora, Colorado 80010, United States
  • Children's National Medical Center /ID# 1140-1122
    Washington, District of Columbia 20010, United States
  • Jackson Memorial Hospital, University of Miami /ID# 1140-0647
    Miami, Florida 33136-1096, United States
  • Florida Hospital Cancer Institute/Adventist Health System/Sunbelt, Inc /ID# 1140-1121
    Orlando, Florida 32804, United States
  • Emory University, Winship Cancer Institute /ID# 1140-0033
    Atlanta, Georgia 30322, United States
  • Emory University/Winship Cancer Institute /ID# 1140-1179
    Atlanta, Georgia 30322, United States
  • University of Chicago /ID# 1140-0126
    Chicago, Illinois 60637, United States
  • Loyola University /ID# 1140-0713
    Maywood, Illinois 60153, United States
  • Indiana University Melvin and Bren Simon Cancer Center /ID# 1140-0010
    Indianapolis, Indiana 46202-5112, United States
  • University of Kentucky /ID# 1140-1140
    Lexington, Kentucky 40508-2678, United States
  • University of Louisville Hospital /ID# 1140-1131
    Louisville, Kentucky 40202, United States
  • University of Maryland /ID# 1140-0205
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital Cancer Center /ID# 1140-0020
    Boston, Massachusetts 02114, United States
  • Boston Childrens Hospital /ID# 1140-1615
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute /ID# 1140-0349
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer In /ID# 1140-0130
    Detroit, Michigan 48201, United States
  • University of Minnesota /ID# 1140-0807
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic, Rochester, MN /ID# 1140-0240
    Rochester, Minnesota 55905, United States
  • Hackensack University Medical Center/ John Theurer Cancer Center /ID# 1140-0343
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of NJ /ID# 1140-0803
    New Brunswick, New Jersey 08903, United States
  • Montefiore Medical Center - Moses Campus /ID# 1140-0120
    Bronx, New York 10467, United States
  • New York Presbyterian Hospital/Weill Cornell Med College /ID# 1140-0200
    New York, New York 10021, United States
  • Stony Brook University Medical Center /ID# 1140-0719
    New York, New York 10021, United States
  • Columbia University Medical Center, MS-CHONY /ID# 1140-1124
    New York, New York 10032-1559, United States
  • Weill Cornell Physicians - Hematologic Malignancies & Bone Marrow Transplant /ID# 1140-0019
    New York, New York 10065, United States
  • University of Rochester Cancer Center /ID# 1140-0127
    Rochester, New York 14642-0001, United States
  • University of North Carolina - Lineberger Comprehensive Cancer Center /ID# 1140-1133
    Chapel Hill, North Carolina 27516, United States
  • Univ Hosp Cleveland /ID# 1140-0941
    Cleveland, Ohio 44106, United States
  • University of Pittsburgh - UPMC (Hillman Cancer Center) /ID# 1140-0050
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina, MUSC /ID# 1140-0738
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center Vanderbilt Ingram Cancer Center /ID# 1140-0024
    Nashville, Tennessee 37232-5280, United States
  • Methodist San Antonio /ID# 1140-1118
    San Antonio, Texas 78229-3710, United States
  • Fred Hutchinson Cancer Research Center /ID# 1140-0404
    Seattle, Washington 98109, United States
  • West Virginia University /ID# 1140-1090
    Morgantown, West Virginia 26506, United States
  • The Kinghorn Cancer Centre /ID# 1140-1165
    Darlinghurst, New South Wales 2010, Australia
  • Westmead Hospital /ID# 1140-0848
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital /ID# 1140-0190
    Herston, Queensland 4029, Australia
  • Royal Children's Hospital/ID# 1140-1154
    Parkville, Victoria 3052, Australia
  • Royal Melbourne Hospital (RMH) /ID# 1140-0633
    Parkville, Victoria 3052, Australia
  • Fiona Stanley Hospital /ID# 1140-0880
    Perth, Western Australia 6000, Australia
  • Univ. Klinik for Innere Medizin, Klinische Abteilung for Hematologie, Graz /ID# 1140-0373
    Graz, 8036, Austria
  • Krankenhaus der Elisabethinen Linz /ID# 1140-0849
    Linz, 4020, Austria
  • University of British Columbia (UBC) - Vancouver General Hospital (VGH) /ID# 1140-1166
    Vancouver, British Columbia V5Z 1M9, Canada
  • The Ottawa Hospital Regional Cancer Center /ID# 1140-0159
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre /ID# 1140-0043
    Toronto, Ontario M5G 2M9, Canada
  • CHU Sainte-Justine /ID# 1140-1143
    Montreal, Quebec H3T 1C5, Canada
  • The First Affiliated Hospital of Soochow University /ID# 1140-1208
    Suzhou, Jiangsu 215006, China
  • Chinese PLA General Hospital /ID# 1140-1198
    Beijing, 100853, China
  • Nanfang Hospital /ID# 1140-1379
    Guangzhou Shi, 510000, China
  • UHC Zagreb /ID# 1140-1169
    Zagreb, 10000, Croatia
  • Hopital Saint-Louis - Institut Hematologie Centre Hayem CHU /ID# 1140-0735
    Paris, Ile-de-France 75010, France
  • Hopital de Brabois /ID# 1140-0775
    Vandoeuvre-lès-nancy, Meurthe-et-Moselle 54511, France
  • CHU Amiens Groupe hospitalier Sud /ID# 1140-1205
    Amiens, 80054, France
  • CHU de GRENOBLE Alpes /ID# 1140-1058
    Grenoble, 38043, France
  • Centre Hospitalier Regional Universitaire de Lille /ID# 1140-0750
    Lille, 59037, France
  • CHU de Nantes /ID# 1140-0520
    Nantes, 44093, France
  • Groupe Hospitalier Pitie-Salpetriere /ID# 1140-0918
    Paris, 33000, France
  • Robert Bosch Hospital /ID# 1140-1160
    Stuttgart, Baden-Wuerttemberg 70376, Germany
  • Universitatsklinikum Munster /ID# 1140-1195
    Munster, Niedersachsen 48149, Germany
  • Universitaetsklinikum Dresden /ID# 1140-1367
    Dresden, 01307, Germany
  • Hannover Medical School /ID# 1140-1141
    Hannover, 30625, Germany
  • Dr. Haunerschen Kinderspital /ID# 1140-1142
    Munich, 80337, Germany
  • University Hospital of Regensburg /ID# 1140-1446
    Regensburg, 93053, Germany
  • St. Laszlo Hospital /ID# 1140-1164
    Budapest, 1097, Hungary
  • IRCCS Ospedale Pediatrico Bambino Gesu /ID# 1140-1150
    Rome, Lazio 00165, Italy
  • A.O. Univ. Ospedali Riuniti /ID# 1140-0932
    Ancona, Marche 60126, Italy
  • ASST Papa Giovanni XXIII /ID# 1140-1231
    Bergamo, 24127, Italy
  • Ospedale San Raffaele IRCCS /ID# 1140-0523
    Milan, 20132, Italy
  • University of Torino /ID# 1140-1268
    Torino, 10124, Italy
  • Centro Trapianti Cellule Staminali, Ospedale Infantile Regina Margherita /ID# 1140-1156
    Turin, 10126, Italy
  • Anjou Kousei Hospital /ID# 1140-1435
    Anjo, Aichi 446-8602, Japan
  • Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital /ID# 1140-1437
    Hiroshima-shi, Hiroshima 730-8619, Japan
  • Kobe City Medical Center General Hospital /ID# 1140-1438
    Kobe-shi, Hyogo 650-0047, Japan
  • Hyogo College of Medicine College Hospital /Id# 1140-1434
    Nishinomiya-shi, Hyogo 663-8501, Japan
  • Duplicate_University of Tsukuba Hospital /ID# 1140-1445
    Tsukuba-shi, Ibaraki 305-8576, Japan
  • Tokai University Hospital /ID# 1140-1444
    Isehara-shi, Kanagawa 259-1193, Japan
  • Duplicate_Kurashiki Central Hospital /ID# 1140-1442
    Kurishiki-shi, Okayama 710-8602, Japan
  • Okayama University Hospital /ID# 1140-1430
    Okayama-shi, Okayama 700-8558, Japan
  • Osaka Women's and Children's Hospital /ID# 1140-1440
    Izumi-Shi, Osaka 594-1101, Japan
  • Osaka City University Hospital /ID# 1140-1157
    Osaka-shi, Osaka 545-8586, Japan
  • Dup_Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital /ID# 1140-1439
    Bunkyo-ku, Tokyo 113-8677, Japan
  • National Center for Child Health and Development /ID# 1140-1443
    Setagaya-ku, Tokyo 157-8535, Japan
  • Kumamoto Medical Center /ID# 1140-1431
    Kumamoto, 860-0008, Japan
  • Hokkaido University Hospital /ID# 1140-1436
    Sapporo, 060-8648, Japan
  • Kyungpook National Univ Hosp /ID# 1140-1153
    Daegu, Daegu Gwang Yeogsi 41944, Korea, Republic of
  • Yonsei University Health System, Severance Hospital /ID# 1140-0927
    Seodaemun-gu, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Samsung Medical Center /ID# 1140-0925
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
  • Cath Univ Seoul St Mary's Hosp /ID# 1140-0928
    Seoul, Seoul Teugbyeolsi 06591, Korea, Republic of
  • SoonChunHyang University Seoul /ID# 1140-1163
    Seoul, 04401, Korea, Republic of
  • Asan Medical Center /ID# 1140-0963
    Seoul, 05505, Korea, Republic of
  • National University Cancer Institute - National University Health System /ID# 1140-1155
    Singapore, 119228, Singapore
  • Singapore General Hospital /ID# 1140-1162
    Singapore, 169608, Singapore
  • Hospital Clinic /ID# 1140-0533
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau /ID# 1140-0535
    Barcelona, 08041, Spain
  • Hospital Universitario Virgen del Rocio /ID# 1140-0863
    Sevilla, 41013, Spain
  • Hospital Clinico Universitario de Valencia /ID# 1140-1145
    Valencia, 46010, Spain

Showing the first 100 of 102 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Mar 2020, 34 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Nov 9, 2016
StartActual
May 11, 2017
Primary completionActual
Mar 27, 2020
CompletionActual
Jul 12, 2021
Results first posted
May 4, 2021
Last update
Mar 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02959944
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
May 11, 2017
Primary completion
Mar 27, 2020
Completion
Jul 12, 2021
Results posted
May 4, 2021
Last update
Mar 30, 2023

Study contacts

Justin Wahlstrom, MD
study director · Pharmacyclics LLC.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion